rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy

Table 3 Bcl-2 expression in gastric cancer cells 48 h after treatment with rAd-p53, oxaliplatin or rAd-p53 plus oxaliplatin

Treatment	Gastric cancer cell line
	rAd-p53 (vp/mL)	OXA (μg/mL)	SGC-7901	BGC-823	HGC-27
OXA	0	3.2	26.32 ± 1.21ea	47.53 ± 1.13ea	56.64 ± 1.33ea
rAd-p53	5 × 106	0	28.62 ± 1.07ca	58.23 ± 1.04ca	61.23 ± 1.07ca
	5 × 107	0	24.34 ± 1.05ca	46.26 ± 1.31ca	49.54 ± 1.14ca
	5 × 108	0	18.62 ± 1.32ca	40.81 ± 1.15ca	47.34 ± 1.06ca
	5 × 109	0	15.37 ± 1.51ca	38.37 ± 1.08ca	44.31 ± 1.03ca
rAd-p53+ OXA	5 × 106	3.2	21.76 ± 1.16eca	35.63 ± 1.41eca	38.18 ± 1.08eca
	5 × 107	3.2	18.34 ± 1.24eca	32.37 ± 1.07eca	35.71 ± 2.02eca
	5 × 108	3.2	16.22 ± 1.02eca	29.27 ± 1.13eca	32.91 ± 1.24eca
	5 × 109	3.2	13.14 ± 1.07eca	26.74 ± 1.02eca	29.84 ± 1.57eca
Control	0	0	38.97 ± 1.06	73.71 ± 2.02	84.03 ± 1.02

^aP < 0.05 vs control;

^cP < 0.05, rAd-p53 vs rAd-p53 + oxaliplatin (OXA) with the same dose of rAd-p53;

^eP < 0.05, OXA vs rAd-p53 + OXA with the same dose of OXA.